CV

a) Publication
1. Bose C K. (2009) Contrasting screening statistics of cervical cancer as opposed to ovarian cancer
Nature. (Letter) In press
2. Bose C K. (2009) Is ramdomised trial of neoadjuvant chemotherapy of ovarian cancer necessary? (Letter) Gynecologic Oncology. In press
3. Bose C K. (2009) Bilateral tubercular ovarian cyst presenting with vertigo. Nepal Journal of Obstetrics & Gynaecology. In press
4. Bose C K. (2009) Mukhopadhyay A, et al Cesarean delivery in a patient with hypoplastic anemia with a very low refractory platelet level. J Turkish-German Gynecol Assoc; 10: 49-51
5. Bose C K. (2009) Canonical Discriminant Function (Z) could be more efficient than Mahalanobis Distance (D2) in differentiating groups: a case in screening of ovarian cancer in a multivariate system analysis using enzyme markers. Journal of Modern and Applied Statistical Methods (JMASM). In press.
6. Bose C K. Sarkar B, Jelinek H. Role of nonlinear dynamics in endocrine feedback. Chaos and Complexity Letters. 3(3): 251-272
7. Bose C K. (2008) Comiphene may not cause neoplasia in ovary: an animal study on ovarian morphology, biochemistry and histochemistry. Journal of the Turkish-German Gynaecology Association (JTGGA). www.jtgga.org ; 9(3): 158-163
8. Bose C K. (2008) Follicle stimulating hormone receptor in ovarian surface epithelium and epithelial ovarian cancer. Oncology Research. 17(5): 231-238.
9. Bose C K, Bose B, Basu A, Basu S. (2008) Liposomal Doxorubicin in Suspected Ovarian Carcinoma Patient with Very Low Creatinine Clearance Test Value, Medscape J Med. 10(3): 53. http://www.medscape.com/viewarticle/570175
10. Bose C K. (2007) Follicle stimulating hormone receptor (FSHR) antagonist and epithelial ovarian cancer (EOC). J Exp Ther Oncol. 6(3):201-4.
11. Bose C K. (2007) Yang,C.Q., Chan,K.Y.K., Ngan,H.Y.S., Khoo,U.S., Chiu,P.M., Chan,Q.K.Y., Xue,W.C., and Cheung,A.N.Y. Single nucleotide polymorphisms of follicle-stimulating hormone receptor are associated with ovarian cancer susceptibility. Carcinogenesis, July 27, 1502-1506.
12. Bose C K. (2007) Comments regarding: Benzyl isothiocyanate (BITC) induces apoptosis in ovarian cancer cells in vitro Kalkunte S, Swamy N, Dizon DS, Brard L. J Exp Ther Oncol. 6(3): 181-2.
13. Bose C K. Possible role of Moringa oleifera lam root in epithelial ovarian cancer. (2007) MedGenMed, Medscape Journal of Medicine. 9(1):26. http://medgenmed.medscape.com/viewarticle/551169
14. Bose C K. Nonlinear dynamics of endocrine feedback in hypothalamico-pituitary-ovarian (HPO) axis and its prospective role in screening and understanding etiology of ovarian cancer. (2007) Journal of the Turkish-German Gynaecology Association (JTGGA). 8 (1): 346-349.www.jtgga.org
15. Bose C K. (2006) Follicle stimulating hormone receptor (FSHR) gene and postmenopausal epithelial ovarian cancer (EOC). Journal of the Turkish-German Gynaecology Association (JTGGA). 7 (4): 76-79.

16. Bose C K, Basu A, Kanjilal S, Basu S. (2005) Giant supratrigonal vesicocervicovaginal fistula- a case report. MedGenMed, Medscape General Medicine. 7(4):74. Available at: http://www.medscape.com/viewarticle/518148?rss
17. Bose C K (2005) Misoprostol as an emergency contraceptive drug. Reproductive BioMedicine Online Vol 11. No 3. 392
18. Bose C K (2005) Role of Nerve growth factor, follicle stimulating hormone receptor and epithelial ovarian cancer, Reproductive BioMedicine Online Vol 11. No 2. 194–197.
19. Abstract accepted for oral presentation in the conference of Federation International du Gynaecology et Obstetrics (FIGO), 2006.
Bose C K (2005) Does hormone replacement therapy (HRT) prevent epithelial ovarian cancer? Reproductive BioMedicine Online Vol. 11, No. 1. 86–92
Bose C K (2004) Nerve growth factor, follicle stimulating hormone receptor and epithelial ovarian cancer. Medical Hypotheses 63(5): 917-918.
Bose C K, Sarkar B, et al (2004) Dynamics of endocrine feedback. http://www.iscid.org/boards/ubb-get_topic-f-26-t-000004.html
Bose C K, Menon U, Dawnay A, Jacobs I J (2001) Gonadotrophin levels in postmenopausal women with epithelial ovarian cancer. J Obstet & Gynaecol of India. 51, No. 6. 147-149
Bose C K (2000) Fertility drug and ovarian cancer. J Obstet & Gynaecol of India. 50 No. 4, 100-101.
Menon U, Riley S C, Thomas J, Bose C, Dawnay A, Evans L W, Groome N P, Jacobs I J (1999) Serum inhibin, activin, follistatin in postmenopausal women with epithelial ovarian cancer. Br J Obstet & Gynaecol. 107, 1069-1074.
Bose C K & Bose B (1996) Evaluation of Lukol in leucorrhoea and leucorrhoea associated with pelvic inflammatory disease – a clinical trial. The Antiseptic. 93(2), 49-50.
Bose C K & Bose B (1995) Clustering of perinatal markers of birth asphyxia and outcome at age five years (Correspondence). Br J Obstet & Gynaecol. 102, 505-506.
Bose C K & Bose B (1994) Cervical contraction: the response of cervix to oxytocic stimulation in the latent phase of labour (Correspondence). Br J Obstet & Gynaecol. 101, 926.
Bose C K & Mukherjea M (1994) Enzymatic tumour markers in ovarian cancer: a multiparametric study. Cancer Lett. 77(1), 39-43.
Bose C K & Bose B (1994) Recent advances in the treatment of ovarian cancer (Correspondence). Br J Obstet & Gynaecol. 101, 830.
Bose C K & Mukherjea M (1993) Alpha-fetoprotein in advanced epithelial ovarian cancer. Br J Obstet & Gynaecol. 100,1148-1149.
Bose C K, Gupta J, Chaudhuri C & Mukherjea M (1993) Evaluation of some biochemical parameters of ovarian cancer patients on chemotherapy. Med Sci Res. 21, 533-534.
Bose C K & Bose B (1993) The loss of baby at birth: the role of bereavement officer (Correspondence). Br J Obstet & Gynaecol. 100, 883.